ライフサイエンスコーパス: short bowel syndrome

1 intestinal differentiation in patients with short bowel syndrome.

2 e development of new therapeutic options for short bowel syndrome.

3 ew option for the treatment of patients with short bowel syndrome.

4 ed for parenteral nutrition in patients with short bowel syndrome.

5 ful option in the treatment of many forms of short bowel syndrome.

6 se data support the use of this operation in short bowel syndrome.

7 ion with glutamine and diet in patients with short bowel syndrome.

8 a child on chronic parenteral nutrition for short bowel syndrome.

9 edure upon intestinal function in a model of short bowel syndrome.

10 l of villus hypertrophy by the creation of a short bowel syndrome.

11 nflammatory bowel disease, malnutrition, and short bowel syndrome.

12 to the treatment of patients suffering from short bowel syndrome.

13 ring therapeutic adaptation in patients with short bowel syndrome.

14 ents with irreversible intestinal failure or short bowel syndrome.

15 parenteral nutrition-dependent subjects with short bowel syndrome.

16 parenteral nutrition in human subjects with short-bowel syndrome.

17 ta on trophic factors in adult patients with short-bowel syndrome.

18 are clinically beneficial for patients with short-bowel syndrome.

19 rowth hormone, and GLP-2 in the treatment of short-bowel syndrome.

20 en with Crohn's disease and in patients with short-bowel syndrome.

21 the treatment of selected patients with the short-bowel syndrome.

22 ery young infants and in those with surgical short-bowel syndrome.

23 bsorption and diarrhea in a patient with the short-bowel syndrome.

24 tion is a feasible therapy for patients with short-bowel syndrome.

25 eatment regimen and placebo in patients with short-bowel syndrome.

26 ten necessary in certain situations, such as short-bowel syndrome.

27 nal transplantation is used in patients with short-bowel syndrome after repeated resections for Crohn

28 ng glucagon-like peptide 2 (GLP2) analogs in short bowel syndrome and Crohn's disease.

29 lantation has become an accepted therapy for short bowel syndrome and other types of intestinal failu

30 e performed in an emaciated patient with the short-bowel syndrome and ileostomy in whom parenteral nu

31 celiac disease, disaccharidase deficiencies, short bowel syndrome, and Crohn disease are discussed.

32 Patients with the short bowel syndrome are maintained on long-term total p

33 ate-low fat (HCLF) diet on gut adaptation in short-bowel syndrome are unclear.

34 ntrolled, crossover study in 8 patients with short-bowel syndrome (average small bowel length, 71 cm;

35 s recommended for PN-dependent patients with short-bowel syndrome before and after transplantation fo

36 nce on parenteral nutrition in patients with short bowel syndrome by promoting enterocytic proliferat

37 Patients with congenital short-bowel syndrome (CSBS) are born with a substantial

38 pplementation were reviewed in patients with short-bowel syndrome, during cancer chemotherapy and in

39 Diagnoses were short bowel syndrome in 12 patients (27%), intestinal en

40 cted infants with liver failure secondary to short bowel syndrome in whom complete enteral autonomy i

41 studies (MBSs) of stable adult patients with short bowel syndrome, intestinal failure (IF) and depend

42 Short bowel syndrome is a morbid product of massive smal

43 Short bowel syndrome is an acquired condition in which t

44 The standard therapy for short bowel syndrome is total parenteral nutrition, whic

45 Although fat malabsorption in the short-bowel syndrome is caused in part by decreased bile

46 Short-bowel syndrome is the malabsorptive state that fol

47 Patients with short bowel syndrome lack sufficient functional intestin

48 timulation with teduglutide in patients with short bowel syndrome might be greater if the more numero

49 Short bowel syndrome occurs when a shortened intestine c

50 patients with intestinal failure because of short-bowel syndrome remain controversial.

51 Short bowel syndrome remains a condition of high morbidi

52 ematurity, low birth weight, duration of PN, short bowel syndrome requiring multiple laparotomies, an

53 redisposing this child to infection included short-bowel syndrome requiring total parenteral nutritio

54 The indications for HPN were short bowel syndrome (SBS) (59%), PNDD (14%), congenital

55 an update of recent advances in the areas of short bowel syndrome (SBS) and small bowel transplantati

56 d the GLP-2 clinical development program for short bowel syndrome (SBS) are reviewed.

57 Short bowel syndrome (SBS) can lead to intestinal failur

58 Short bowel syndrome (SBS) is a serious malabsorption di

59 rolonged survival in pediatric patients with short bowel syndrome (SBS) is now possible because of pa

60 Short bowel syndrome (SBS) may induce a plethora of clin

61 cantly improved the outcome of neonates with short bowel syndrome (SBS) who require parenteral nutrit

62 l of the small bowel (SRSB) in patients with short bowel syndrome (SBS) who were "permanently" depend

63 r parenteral support volume in patients with short bowel syndrome (SBS) with intestinal failure, incr

64 surgical options for managing patients with short bowel syndrome (SBS).

65 small bowel (SB) dilatation in children with short bowel syndrome (SBS).

66 an be a lethal complication in children with short bowel syndrome (SBS).

67 ll bowel (SRSB) is proposed in patients with short-bowel syndrome (SBS) as a rehabilitative therapy,

68 financial charges incurred by patients with short-bowel syndrome (SBS).

69 ata about these indexes exist in humans with short-bowel syndrome (SBS).

70 yme could represent novel targets for future short bowel syndrome therapies.

71 A 49-year-old woman with short bowel syndrome underwent multivisceral transplanta

72 Short-bowel syndrome usually results from surgical resec

73 egulation of IEL-derived KGF expression, and short bowel syndrome was associated with an up-regulatio

74 malignancy (particularly colonic carcinoma), short bowel syndrome (where factors such as growth hormo

75 He subsequently developed short-bowel syndrome, which required him to have total p

76 ved for the treatment of adult patients with short bowel syndrome who are dependent on parenteral sup

77 n with a long history of Crohn's disease and short-bowel syndrome who had only 2 feet of small intest

78 uid and nutrient absorption in patients with short bowel syndrome with intestinal failure (SBS-IF).

79 ole-body protein metabolism in patients with short-bowel syndrome with intestinal failure (SBS-IF) to